In addition to the new Pfizer and Moderna boosters, Novavax also expects to have an updated vaccine on the market soon. The ...

Ward said it would be good to see data from studies of other variant vaccine boosters to compare to the Moderna combination. Expert advisors "must already be thinking about the population at risk ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Now, what about the second booster, which, for people who received Pfizer and Moderna, would be their fourth shot? Who's eligible? Well, right now, you're eligible for a second COVID-19 booster if ...

Booster shots are here — for some Americans, at least. US regulators have updated their recommendations as to who should get a third dose of Pfizer and Moderna's vaccines. The Food and Drug ...

Boosters aren’t currently recommended for anyone else in the U.S., though regulators and CDC officials will soon decide if any Moderna and Johnson & Johnson recipients should also get extra doses.

Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

The UK has become the first country in the world to authorise an updated COVID-19 booster vaccine directed at the Omicron variant, giving a green light to Moderna's mRNA-1273.214 shot.

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.